D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
OVID holding history
Ovid Therapeutics Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
OVID overviewAll 13F holders of OVIDFull Q2 2026 holdings
- Shares (Q2 2026)
- 36,877
- Value
- $99.2K
- % of portfolio
- <0.1%
- Quarters held
- 14
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 36,877 | $99.2K | <0.1% | +36,877 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −71,264−100.0% | Sold out | Holders |
| Q1 2024 | 71,264 | $217.4K | <0.1% | −7,003−8.9% | Reduced | Holders |
| Q4 2023 | 78,267 | $252.0K | <0.1% | −6,041−7.2% | Reduced | Holders |
| Q3 2023 | 84,308 | $323.7K | <0.1% | −22,974−21.4% | Reduced | Holders |
| Q2 2023 | 107,282 | $351.9K | <0.1% | −231,878−68.4% | Reduced | Holders |
| Q1 2023 | 339,160 | $875.0K | <0.1% | −167,167−33.0% | Reduced | Holders |
| Q4 2022 | 506,327 | $941.8K | <0.1% | −184,996−26.8% | Reduced | Holders |
| Q3 2022 | 691,323 | $1.27M | <0.1% | −198,041−22.3% | Reduced | Holders |
| Q2 2022 | 889,364 | $1.91M | <0.1% | +663+0.1% | Added | Holders |
| Q1 2022 | 888,701 | $2.79M | <0.1% | +129,605+17.1% | Added | Holders |
| Q4 2021 | 759,096 | $2.44M | <0.1% | +30,166+4.1% | Added | Holders |
| Q3 2021 | 728,930 | $2.45M | <0.1% | −16,985−2.3% | Reduced | Holders |
| Q2 2021 | 745,915 | $2.92M | <0.1% | +160,210+27.4% | Added | Holders |
| Q1 2021 | 585,705 | $2.35M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.